BMC Cancer · 2021 · 13 citations · 33 references
MedicineBiostatisticsOncologyBreast OncologyMolecular OncologySurvival AnalysisBreast Cancer OncologyCancer BiomarkersCancer Survival AnalysisMale Breast CancerMolecular Tumor ProfilingBreast Cancer GenomicsBreast Cancer Molecular SubtypesBreast Cancer PrognosisCox RegressionDisease-specific SurvivalPrognostic Expression SignaturesPrognostic Factors AnalysisPropensity Score Adjustment
BACKGROUND: The purpose of this study was to explore clinicalpathology features, molecular features and outcome of male breast cancer patients who expressed ER, PR as well as HER-2, namely triple-positive male breast cancer (TP-MBC), and compared them with triple-positive female breast cancer patients (TP-FBC). METHODS: TP-MBC and TP-FBC from 2010 to 2017 were selected from the Surveillance, Epidemiology, and End Results database (SEER). Kaplan-Meier plotter and multivariable Cox regression model were applied to analyse the difference between TP-MBC and TP-FBC on cancer-specific survival (CSS) and overall survival (OS). Propensity score matched (PSM) analysis was used to ensure well-balanced characteristics. 7 cases TP-MBC and 174 cases TP-FBC patients with the genomic and clinical information were identified from the cohort of The Cancer Genome Atlas (TCGA) and the Memorial Sloan Kettering (MSK). RESULT: 336 TP-MBC and 33,339 TP-FBC patients were taken into the study. The percentages of TP-MBC in MBC patients were higher than the rates of TP-FBC in FBC patients from 2010 to 2017 except 2012. Compared with TP-FBC, more TP-MBC were staged III (17.9% vs. 13.5%) or stage IV (11.0% vs. 6.9%). TP-MBC were more frequently to be older than 65-years-old (47.0% vs. 29.3%), Balck (15.2% vs. 10.8%), ductal carcinoma (91.7% vs. 84.4%) and metastases to lung (4.5% vs. 2.1%) or bone (8.6% vs. 4.7%). TP-MBC had worse OS and CSS than TP-FBC in all stages (P < 0.001). In multivariable prediction model of TPBC, male patients had a higher risk than female. Lastly, the worse OS (P < 0.001) and CSS (P = 0.013) were seen in the 1:3 PSM analysis between TP-MBC and TP-FBC. Genomic analysis revealed that TP-MBCs have some notable rare mutations, like ERBB2, ERBB3, RB1, CDK12, FGFR2, IDH1, AGO2, GATA3, and some of them are not discovered in TP-FBC. CONCLUSION: TP-MBC had a worse survival than TP-FBC, and there were different genomic features between two groups. Current knowledge and treatment to TP-MBC maybe inadequate and remain to be explored.
33
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Sharon H. Giordano, Deborah S. Cohen, Aman U. Buzdar et al. · Cancer · 2004 · 786 citations · Full text
Medicine, Oncology, Breast Oncology +13
Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer
William F. Anderson, Ismail Jatoi, Julia Tse et al. · Journal of Clinical Oncology · 2009 · 489 citations · Full text
Medicine, Cancer Biology, Oncology +15